Abstract：【Objective】To observe the clinical effect of bevacizumab combined with 5-fluorouracil (5-Fu), leucovorin (LV) and oxaliplatin (L-OHP) (FOLFOX4) chemotherapy regimen in the treatment of advanced rectal cancer. 【Methods】Eighty-six patients with advanced rectal cancer who were admitted to our hospital were selected as study subjects. According to order of hospitalization, the subjects were numbered and were randomized into a control group and an observation group, with 43 cases in each group. Both groups received FOLFOX4 first-line chemotherapy. The observation group was treated with bevacizumab in addition to this. The treatment effects,toxicity and survival rate were compared between the two groups. Both groups were followed up for 2 years. The survival rate was recorded and the quality of life was evaluated by European organization for research and treatment of cancer quality of life questionnaire (EORTC QLC-CR37 ). 【Results】① The total response rate in the observation group was higher than that in the control group (P<0.05). ② There was no significant difference in the incidence of toxic and side effects between the two groups (P>0.05). ③ After 2 years of follow-up, the overall survival rate of the observation group was higher than that of the control group (P<0.05). ④ After 3, 6, 12 and 24 months of treatment, the quality of life scores of both groups decreased (P<0.05), and the decrease in the observation group was greater than that in the control group (P<0.05). 【Conclusion】The application of bevacizumab combined with FOLFOX4 chemotherapy in treatment of advanced rectal cancer has a high total response rate, can improve the 2-year survival rate of patients and can optimize the quality of life.
胡春霞,姜维美,李晓敏,李秀翠. 贝伐珠单抗联合FOLFOX4化疗方案治疗晚期直肠癌的临床疗效[J]. 医学临床研究, 2016, 33(11): 2107-2110.
HU Chun-xia, JIANG Wei-mei, LI Xiao-min,et al. Clinical Study on Bevacizumab Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Rectal Cancer. JOURNAL OF CLINICAL RESEARCH, 2016, 33(11): 2107-2110.
2016, Vol. 33 
